Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 6.4% - Should You Sell?

Key Points

• Shares fell 6.4% to about $12.06 on Wednesday with trading volume roughly 32% below average, though the stock is trading above its 50‑day ($9.88) and 200‑day ($7.20) moving averages.
• Analysts are generally positive—two firms (HC Wainwright and JonesTrading) rate the stock a "Buy" and the consensus price target is $15.
• Armata is a clinical‑stage biotech developing bacteriophage therapies for antibiotic‑resistant infections, but it reported a large quarterly loss (EPS -$3.42 vs. -$0.19 estimate) and is expected to post about -$0.95 EPS for the year, with institutional ownership around 3.6%.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) shares dropped 6.4% during mid-day trading on Wednesday . The stock traded as low as $12.05 and last traded at $12.06. Approximately 28,775 shares traded hands during trading, a decline of 32% from the average daily volume of 42,483 shares. The stock had previously closed at $12.88.

Analyst Ratings Changes

ARMP has been the topic of several research analyst reports. HC Wainwright boosted their target price on Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, February 23rd. JonesTrading initiated coverage on Armata Pharmaceuticals in a research note on Monday, January 5th. They set a "buy" rating and a $15.00 target price on the stock. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, Armata Pharmaceuticals has a consensus rating of "Buy" and an average target price of $15.00.

Armata Pharmaceuticals Price Performance

The company has a market capitalization of $441.76 million, a PE ratio of -2.50 and a beta of 1.38. The company has a 50 day moving average of $9.88 and a two-hundred day moving average of $7.20.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($3.23). The company had revenue of $1.09 million during the quarter, compared to the consensus estimate of $0.74 million. On average, equities analysts anticipate that Armata Pharmaceuticals, Inc. will post -0.95 EPS for the current year.

Institutional Investors Weigh In On Armata Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARMP. SeaCrest Wealth Management LLC grew its stake in Armata Pharmaceuticals by 17.3% in the fourth quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company's stock worth $274,000 after purchasing an additional 6,034 shares during the period. Geode Capital Management LLC grew its stake in Armata Pharmaceuticals by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company's stock worth $690,000 after purchasing an additional 5,342 shares during the period. Goldman Sachs Group Inc. purchased a new stake in Armata Pharmaceuticals in the fourth quarter worth $284,000. Renaissance Technologies LLC grew its stake in Armata Pharmaceuticals by 65.9% in the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company's stock worth $430,000 after purchasing an additional 27,200 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Armata Pharmaceuticals in the fourth quarter worth $108,000. 3.57% of the stock is owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.